China drafts guidelines for use of real-world data

Five months after FDA released a framework for use of real-world data in drug development, China’s Center for Drug Evaluation followed with its first guidelines for the data in May, which the country’s large population may uniquely position it to utilize for drug development and regulatory decisions. By clarifying the government's position, the draft guidelines could incentivize industry use of

Read the full 607 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers